Published in Health and Medicine Week, October 2nd, 2006
Acapodene, a selective estrogen receptor modulator, is intended to exploit a new strategy of estrogen receptors modulation which could translate into a tangible clinical benefit in both the chemoprevention of prostate cancer in high-risk men and the treatment of multiple...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.